Form 4: Regeneron EVP Joseph LaRosa Executes Stock Option and Disposes of Shares

Regeneron's EVP, General Counsel, and Secretary, Joseph LaRosa, exercised stock options and disposed of shares to cover tax obligations.

Summary

• On June 24, 2024, Joseph LaRosa, EVP, General Counsel, and Secretary of Regeneron Pharmaceuticals, Inc., exercised stock options to acquire 14,450 shares of common stock at a price of $555.67 per share.
• Following the exercise of the options, LaRosa disposed of 11,084 shares of common stock at a price of $1,060.13 per share.
• These transactions resulted in LaRosa holding 39,803 shares directly and 371 shares indirectly through a 401(k) plan.

Sentiment

Score: 5

Explanation: The document reflects routine insider transactions, which are neither particularly positive nor negative. It's a neutral disclosure required by regulations.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions, providing transparency into the trading activities of company executives. It is common for executives to exercise stock options and sell a portion of the acquired shares to cover tax obligations.

Comparison to Industry Standards

• Executive compensation practices, including stock options, are common in the pharmaceutical industry.
• Companies like Amgen (AMGN) and Gilead Sciences (GILD) also utilize stock options as part of their executive compensation packages.
• The vesting schedules and exercise prices are generally aligned with industry norms to incentivize long-term performance.

Stakeholder Impact

• The transactions have a minimal direct impact on shareholders, employees, customers, suppliers, and creditors.
• The disclosure provides transparency regarding executive compensation and stock ownership.

Key Dates